APP and Alzheimer disease: Oxyphylla A, a compound extracted from Alpinia oxyphylla, was tested in in vivo and in vitro AD models at various concentrations (12.5-100 μM) and the results showed that it could reduce the expression of APP and Aβ and alleviate cognitive deficits in SAMP8 mice.